Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $22.7 million.

  • Beam Therapeutics' Share-based Compensation fell 2304.54% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.0 million, marking a year-over-year decrease of 800.19%. This contributed to the annual value of $120.7 million for FY2024, which is 2231.69% up from last year.
  • As of Q3 2025, Beam Therapeutics' Share-based Compensation stood at $22.7 million, which was down 2304.54% from $24.4 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Share-based Compensation ranged from a high of $31.6 million in Q2 2024 and a low of $4.6 million during Q1 2021
  • Its 5-year average for Share-based Compensation is $22.2 million, with a median of $22.7 million in 2025.
  • As far as peak fluctuations go, Beam Therapeutics' Share-based Compensation soared by 33054.45% in 2021, and later crashed by 2304.54% in 2025.
  • Quarter analysis of 5 years shows Beam Therapeutics' Share-based Compensation stood at $15.5 million in 2021, then skyrocketed by 45.14% to $22.5 million in 2022, then increased by 0.52% to $22.6 million in 2023, then skyrocketed by 33.61% to $30.2 million in 2024, then fell by 24.72% to $22.7 million in 2025.
  • Its last three reported values are $22.7 million in Q3 2025, $24.4 million for Q2 2025, and $26.7 million during Q1 2025.